Atara's Phase 2 ATA188 for non-active PMS misses primary endpoint; cash runway extended beyond Q3 2025

Atara Biotherapeutics, Inc.

EMBOLD misses primary endpoint; treatment arm CDI 6% vs 33% in Phase 1; placebo rate 16% exceeded expected 4-6%.
No new safety signals observed; favorable safety profile for ATA188 in the study.
Company plans significant expense reductions on ATA188; focuses on allogeneic CAR-T pipeline; cash runway extended beyond Q3 2025.
Catalysts: ATA3431 preclinical data at ASH Dec 2023; Phase 1 data for ATA3219 in B-NHL expected H2 2024.
Tab-cel partnership with Pierre Fabre provides additional payments and significant double-digit royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.